Pages that link to "Q27303674"

The following pages link to Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs (Q27303674):

Displaying 19 items.

• Chemoprevention of Breast Cancer by Dietary Polyphenols (Q26773449) (← links)
• Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis (Q37644800) (← links)
• Fatty acid synthase is a primary target of MiR-15a and MiR-16-1 in breast cancer (Q37694670) (← links)
• Fatty acid synthase expression and its association with clinico-histopathological features in triple-negative breast cancer (Q44076458) (← links)
• Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2 /ER mammary carcinoma (Q47114555) (← links)
• DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer (Q47170552) (← links)
• Deciphering metabolic rewiring in breast cancer subtypes (Q47836759) (← links)
• Fatty acid synthase (FASN) as a therapeutic target in breast cancer. (Q50044384) (← links)
• In vitro Biological Effects of Sulforaphane (SFN), Epigallocatechin-3-gallate (EGCG), and Curcumin on Breast Cancer Cells: A Systematic Review of the Literature. (Q50222488) (← links)
• Obesity-associated Breast Cancer: Analysis of risk factors (Q50957755) (← links)
• Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugs (Q57106864) (← links)
• Cancer Chemoprevention: Classic and Epigenetic Mechanisms Inhibiting Tumorigenesis. What Have We Learned So Far? (Q60938839) (← links)
• EGCG-Derivative G28 Shows High Efficacy Inhibiting the Mammosphere-Forming Capacity of Sensitive and Resistant TNBC Models (Q64089216) (← links)
• Anoikis resistant mediated by FASN promoted growth and metastasis of osteosarcoma (Q64090368) (← links)
• (-)-Epigallocatechin 3-Gallate Synthetic Analogues Inhibit Fatty Acid Synthase and Show Anticancer Activity in Triple Negative Breast Cancer (Q88643680) (← links)
• Lipid metabolic reprogramming as an emerging mechanism of resistance to kinase inhibitors in breast cancer (Q90749099) (← links)
• Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer (Q91660453) (← links)
• Towards personalized treatment for early stage HER2-positive breast cancer (Q91974174) (← links)
• Membrane disruption, but not metabolic rewiring, is the key mechanism of anticancer-action of FASN-inhibitors: a multi-omics analysis in ovarian cancer (Q99350111) (← links)